Neil Flanagan

Neil Flanagan has a diverse and extensive work experience in the pharmaceutical industry. Neil is currently serving as the Director of CMC at Apollo Therapeutics since October 2021.

Prior to this, Neil worked at Sosei Heptares from June 2018 to October 2021 as an Associate Director CMC, Drug Product. In this role, they led preclinical and clinical drug product development for small molecule and peptide projects. Neil was responsible for formulation across the portfolio, including CRO/CDMO selection and management, as well as contributing to CMC regulatory submissions.

From September 2016 to June 2018, Neil was employed by GSK as the Formulation Developability and CMC technical leader. Their responsibilities included formulation and CMC management of various preclinical projects, such as oral, inhaled, long-acting parenteral (LAP), and developing world assets. Neil was also a technical leader in the area of biopharmaceutics, drug delivery, and preformulation characterization for risk management of assets into Clinical Development.

Neil's work experience at Neusentis (Pfizer) spans from September 1998 to September 2016. Neil held multiple roles during this period, starting as a Senior Principal Scientist and later becoming the Drug Delivery Leader. Their responsibilities included leading formulation initiatives on concurrent projects, managing external collaborations on novel drug delivery technologies, and authoring CMC drug product IND and IMPD documents. Neil also set up and led the formulation function for the new Pfizer Research Unit.

Neil's career began at Abbott Laboratories in September 1996, where they worked as an IDC Scientist until September 1997.

Neil Flanagan attended the University of Strathclyde from 1993 to 1998. No degree or field of study information is provided.